CSL Behring receives national marketing authorization of Berinert in Israel.

CSL Behring has been granted national marketing authorisation in Israel to market Berinert for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia. CSL Behring completed a European Mutual Recognition Procedure (MRP) for Berinert for the treatment of acute attacks of HAE, a rare and serious genetic disorder, in 23 European countries in Dec 2008. It was subsequently granted all …